Medicare begins covering GLP-1 obesity drugs for first time, capping patient cost at $50 a month
CMS's Medicare GLP-1 Bridge program launches July 1, giving an estimated 15-20 million eligible beneficiaries access to tirzepatide (Zepbound) and semaglutide (Wegovy) at a $50 monthly cap under a deal struck by the Trump administration with Novo Nordisk and Eli Lilly in late 2025
Add to a list
No lists yet.
developments
-
The Medicare GLP-1 Bridge program launched on July 1. Eligible beneficiaries must obtain a prescription, which triggers a Humana prior-authorization request that providers must complete to certify eligibility. CMS confirmed the program covers Zepbound KwikPen (tirzepatide), Foundayo and Wegovy (semaglutide), but explicitly not Ozempic (which is approved only for diabetes, not obesity). Walgreens issued a launch-day press release confirming it is participating as a dispensing pharmacy and reporting no day-one supply shortages at major distribution centers. Patients already receiving a GLP-1 for diabetes, cardiovascular disease or sleep apnea under Part D are not eligible for the Bridge rate. ↗
Summary
Medicare began covering GLP-1 obesity medications on July 1 for the first time in the programme's 60-year history, under a Centers for Medicare and Medicaid Services demonstration called the Medicare GLP-1 Bridge. Tirzepatide (Zepbound, Eli Lilly) and semaglutide (Wegovy, Novo Nordisk) are the initially approved drugs, with patients paying no more than $50 per month. The programme runs through December 2027. Eligibility requires a body mass index of 35 or above, or a BMI of 30 to 35 with at least one qualifying condition such as uncontrolled hypertension, prediabetes, prior heart attack, chronic kidney disease, or diastolic heart failure. CMS estimates 15 to 20 million Medicare beneficiaries qualify. The $50 price point follows a deal struck by the Trump administration with Eli Lilly and Novo Nordisk in November 2025 as part of broader drug-pricing negotiations.
Why it matters
Medicare Part D had explicitly excluded weight-loss drugs since its creation in 2003; lifting the exclusion via a demonstration programme, even temporarily, sets a precedent that will shape the permanent coverage debate after 2027. With 15 to 20 million potential patients, the programme could add tens of billions in annual revenue to Novo Nordisk and Eli Lilly while testing whether expanded access reduces downstream cardiovascular and diabetes costs for the federal budget.